A question I have been asked in the past is “Can you teach someone to be a consultant?” And the answer? Well, of course you can – but only up...
Read More
‘Time to event’ or ‘survival’ is an important endpoint used in efficacy assessments of medical interventions, particularly in disease areas such as oncology. The Cox proportional hazards (PH) model is…
Continuous outcomes data from trials may be categorised using pre-defined cut-offs to generate ordered categorical outcomes data. Usually the percentage of patients who have improved by certain thresholds are reported…
Network meta-analysis (NMA) is a key tool for researchers and decision makers that allows the efficacy and safety of any number of healthcare interventions to be compared simultaneously. However, a…
One size does not fit all. By creating dynamic data driven Veeva presentations you can tailor the story to a stakeholder's needs, making a presentation pertinent for a specific health...
Read More
5 ways Market Access can benefit from deploying Budget Impact Models via Veeva Veeva has quickly established itself as the industry standard CRM platform for the Pharmaceutical sector, and following its…
Mtech Access were proud to have one of our budget impact models feature at the Veeva Summit. David Niziol presented the secrets to integrating health economic models and market access...
Read More
This video demonstrates the features and functions of a typical iPad budget impact model. This particular example looks at a health economic impact model running in the Veeva platform and...
Read More
Over the last 2 decades there have been many changes in how pharma and medical device manufacturers engage with stakeholders in the field, in terms of content, technology and the…
We recently set ourselves a challenge to transform NICE guidance NG19, the associated costing template and report into a user-friendly iPad budget impact model for payer/commissioner engagement in the field….
